Programme Thesis
The EIC Accelerator is the EU's flagship deep-tech scale-up instrument under Horizon Europe, offering grants up to €2.5M plus equity investment of €1–10M to individual startups and SMEs with innovations at TRL 6–8 ready to create or disrupt European and global markets. It exists because private investors alone cannot bear the risk of truly breakthrough technologies; the EIC acts as patient, first-loss capital to bridge this gap. In 2026 the Open track carries €414M and the Challenges track €220M, with evaluation gatekeeping that accepts roughly 6–8% of all submitted proposals.
Selection Criteria
• Step 1 (Short Proposal – 12-page form + 10-slide pitch deck + 3-min video): evaluated remotely by 4 EIC expert evaluators against three criteria: Excellence (novelty, scientific/technological breakthrough), Impact (market potential, European/global disruption, scale-up plan), and Implementation (team capability, feasibility). Pass/Fail gate.
• Step 2 (Full Proposal – 20-page form + implementation plan + FTO analysis + financial info + LoIs): assessed by a technology expert (individual interview) and a panel of ≥3 domain experts. Scoring threshold: proposals must score ≥13/15 at remote stage to enter jury interviews. Top proposals ranked to 2.5× available grant budget are invited to jury.
• Step 3 (EIC Jury Interview): panel of investors, serial entrepreneurs, industry experts. Pitching 'investment readiness', commercial traction, team, and scale-up ambition. Final GO/NO-GO.
• Evaluation dimensions: (1) Innovation breakthrough / scientific excellence; (2) Market creation / disruption potential; (3) Team experience and execution capacity; (4) Financial sustainability and investment need rationale; (5) Regulatory and IP readiness (FTO analysis mandatory).
• 'Seal of Excellence' awarded to proposals scoring ≥13/15 but not funded, enabling alternative national/regional funding access.
Past Winners / Cohort Profiles
October 2024 cohort (71 companies, €387M): 55% had 11–50 employees, 32% had 2–10 employees; median founding year 2017–2022 (3–7 years old at application). Top sectors: Health 31% (medical devices and pharma dominating), ICT 28% (AI, quantum computing), Environmental Tech 15%, Biotechnology. Top countries: Germany (21%), Netherlands (15%), Spain and Sweden (10% each). Finance type: 79% requested blended finance (grant + equity), 12% grant-only, 9% equity-only. Representative life-science winners: Connecta Therapeutics (rare disease/Fragile X clinical trial), Myopax (muscular dystrophy gene therapy), Vivalyx (donor organ preservation), Treefrog Therapeutics (cell manufacturing), IKTOS (AI + robotics for drug discovery). All winners are registered SMEs with a distinct commercial product, clinical/regulatory roadmap, and active IP strategy. June 2025 round: 40 companies selected from 150 finalists (26% interview success rate). The archetype is a post-seed, VC-backed or bootstrapped SME with at least a functional MVP, some initial customers or clinical data, clear regulatory pathway, and a CEO who pitches investor-grade.
Ideal Candidate Fingerprint
The platonic EIC Accelerator applicant is a 3–6 year-old EU/Horizon-associated-country SME with 5–30 employees, a working prototype or clinical-stage asset at TRL 6–8, ≥1 granted or pending patent, letters of intent from early adopters or clinical partners, and a CEO with deep domain expertise plus demonstrated fundraising or commercial experience. The company has already raised seed funding and is seeking EIC blended finance to complete late-stage development and enter a first commercial market, with a credible addressable market in the hundreds of millions of euros. Sector versatility is real (health/AI/climate/quantum all funded) but the commercial-readiness bar is non-negotiable.
Recommended Framing
Eniola's most defensible angle — if she proceeds at all — is to reframe IMPRINT or TOPOLOGIX (not the CCT model itself) as the primary commercial product: AI-native drug-liability screening or TDA-based drug–protein interaction SaaS platforms, with the CCT framework as proprietary scientific IP underlying them. This pivot to a software product with a credible B2B market (pharma, biotech, CRO) is closer to what EIC Accelerator has funded in the AI/health intersection (e.g., IKTOS, NannyML, Deeploy). Eniola would need to submit Step 1 from Nigeria while simultaneously incorporating ZYCO (or a new entity) in Austria by October 2026 (aligning with her planned Graz MSc move), then submit the full proposal from an EU-registered entity — a difficult but technically legal path given that Austria is an EU Member State.
Watch Out
CRITICAL — Eligibility blocker (hard): Nigeria is not an EU Member State nor associated to Horizon Europe. Third-country applicants can submit a short proposal but MUST establish or relocate an SME to an EU Member State BEFORE submitting the full proposal (Step 2). This requires active company registration in Europe, not just residency intent.
CRITICAL — Programme type mismatch: EIC Accelerator is a commercial scale-up instrument for SMEs, not a research fellowship or grant for individual independent researchers. ZYCO must be a properly constituted SME entity with auditable financials and a scale-up business plan.
HIGH — TRL gap: CCT model is at TRL 3–4 (computational/Bayesian proof-of-concept with no in-vitro, animal, or human validation). EIC Accelerator targets TRL 6–8 (prototype demonstrated in operational environment). IMPRINT and TOPOLOGIX may be closer to TRL 4–5 but would need demonstrable MVPs and at least a letter of intent from an industrial or clinical user to be credible.
HIGH — Budget and investment readiness mismatch: She is seeking $10K–$100K research-style funding; EIC Accelerator provides €0.5M–€2.5M in grants plus equity. Applying without a genuine intent to accept and absorb equity investment is a red flag for the jury.
MEDIUM — No registered company/SME on record: ZYCO appears listed on zyco.org but its legal incorporation status is unclear. EIC requires demonstrable legal entity, financial statements, and employee headcount before Step 2.
MEDIUM — No FTO (freedom-to-operate) analysis yet: the CCT provisional patent is Q3 2026; EIC full proposals require an FTO analysis, and a provisional patent alone is insufficient to show IP protection at scale.
MEDIUM — No clinical or commercial traction: past winners, even at early stage, had LoIs from hospitals, pharma partners, or paying customers. Eniola's endorsements are academic (Berridge, Gershman, Daw, Mattar) — excellent for credibility but insufficient for EIC's commercial jury.